The strengths of our study include a cohort who received standard treatments and long follow-up; a focus on the prognostic value in survival and response to chemotherapy of dynamic changes in Hb levels during treatments, and a probing of anemia’s predictive role in survival plus response to chemotherapy. Here, GSTM1 is linked to anemia (phenotype).